A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer

NCT02120417 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
149
Enrollment
INDUSTRY
Sponsor class

Stopped The study was terminated as other related studies of ruxolitinib did not provide sufficient efficacy to warrant continuation.

Conditions

Interventions

Sponsor

Incyte Corporation